IBM topped a February 2024 industry count of AI-related U.S. patent applications, filing more in 2023 than Google or Microsoft individually -- the direct result of a 2020 decision to stop chasing overall patent-count leadership and focus filings on AI, hybrid cloud, security, and quantum computing instead. Newly loaded USPTO filing records confirm the pattern down to individual applications and grant numbers. IBM's own commercial AI platform, watsonx.ai, is estimated to hold roughly 0.05 percent of the market those patents describe.

Ofinno doesn't make phones, chips, or networking gear. It builds 5G and Wi-Fi technology, patents it, and licenses the patents to the companies that do. Its founder holds more granted US patents than all but nineteen people in the entire record since 1976. The company is the product.

DoAyni's own build of the FDA's Orange Book computes December 19, 2026 as the date Pfizer's Vyndaqel clears its last listed patent, with no generic yet approved -- a real, checkable near-term patent-cliff signal. It is also close to moot: Pfizer pulled Vyndaqel from the U.S. market at the end of 2025, a year before its own patents expire, shifting the franchise entirely to Vyndamax, a drug with patents listed to 2035 and, as of an April 2026 courtroom settlement with three generic makers, a guaranteed floor against generic entry until at least June 1, 2031. The $6.38 billion product's real patent cliff was set in a settlement, not in the patent list itself.